CRO

BMS sees potential for ConcertAI's digital trial service to become 'gold standard' for oncology trials

Bristol Myers Squibb has high expectations for ConcertAI's digital solution for clinical trials, suggesting it could become the "gold standard" for studying oncology therapies.

The Big Pharma has spent the past two years working with the data specialist on the software platform, dubbed Digital Trial Solution. The platform integrates clinical research and practice to accelerate patient identification, contract negations and approvals to help speed up trials.

“The Digital Trial Solution will allow us to accelerate access to innovative, lifesaving cancer medicines to patients,” Venkat Sethuraman, BMS' senior vice president of global biometrics and data sciences, said in a release. “We anticipate this approach will become BMS' gold standard for oncology studies in the future.” 

ConcertAI is focused on moving the industry to digital-only trials that are more streamlined, cost-effective and inclusive of diverse patient populations. The announcement with BMS comes less than two weeks after ConcertAI inked a five-year partnership deal with Louisiana State University Health New Orleans to address diversity in clinical trials in the Gulf South region.

Under that agreement, LSU Health will implement ConcertAI’s ERACE (Engaging Research to Achieve Cancer Care Equity) program that uses AI and real-world data in clinical trials to overcome challenges such as time, money, boosting diversity, retention and recruitment.

Back in March, ConcertAI raised $150 million in series C funding that was earmarked to help scale its software and real-world data solutions for cancer research. The Boston-based company works with CROs, medical societies and regulators across the U.S., Europe and Japan and has also partnered with Johnson & Johnson's Janssen unit.